Comprehensive review: Antitumor necrosis factor agents in inflammatory bowel disease and factors implicated in treatment response

Therapeutic Advances in Gastroenterology

Volumn 6, Issue 4, 2013, Pages 269-293

  Lichtenstein, Gary R ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

adalimumab; antitumor necrosis factor ; certolizumab; Crohn s disease; enzyme linked immunosorbent assay; immunogenicity; inflammatory bowel disease; infliximab; ulcerative colitis

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; CERTOLIZUMAB PEGOL; HYDROCORTISONE; INFLIXIMAB; MERCAPTOPURINE; METHOTREXATE; MONOCLONAL ANTIBODY; PLACEBO; TUMOR NECROSIS FACTOR INHIBITOR;

ANTIBODY PRODUCTION; CHILL; CLINICAL DECISION MAKING; CLINICAL PRACTICE; CROHN DISEASE; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG MONITORING; DRUG SAFETY; DYSPNEA; ENTERITIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEVER; HEADACHE; HUMAN; IMMUNOGENICITY; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATION; INFORMATION RETRIEVAL; INFUSION RELATED REACTION; MAINTENANCE THERAPY; MONOTHERAPY; NAUSEA; PHAGOCYTE; PRIORITY JOURNAL; RECTUM HEMORRHAGE; REMISSION; REVIEW; TREATMENT OUTCOME; TREATMENT RESPONSE; ULCERATIVE COLITIS; WOUND HEALING;

EID: 84878299137     PISSN: 1756283X     EISSN: 17562648     Source Type: Journal    
DOI: 10.1177/1756283X13479826     Document Type: Article

References (63)

1. Afif W. Loftus E. Jr Faubion W. Kane S. Bruining D. Hanson K. et al. (2010) Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease. Am J Gastroenterol 105: 1133–1139.
2. Ainsworth M. Bendtzen K. Brynskov J. (2008) Tumor necrosis factor-alpha binding capacity and anti-infliximab antibodies measured by fluid-phase radioimmunoassays as predictors of clinical efficacy of infliximab in Crohn's disease. Am J Gastroenterol 103: 944–948.
3. Anderson P. (2005) Tumor necrosis factor inhibitors: clinical implications of their different immunogenicity profiles. Semin Arthritis Rheum 34(Suppl. 1): 19–22.
4. Baert F. Noman M. Vermeire S. van Assche G. D'Haens G. Carbonez A. et al. (2003) Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 348: 601–608.
5. Barnes T. Moots R. (2007) Targeting nanomedicines in the treatment of rheumatoid arthritis: focus on certolizumab pegol. Int J Nanomedicine 2: 3–7.
6. Bewtra M. Su C. Lewis J. (2007) Trends in hospitalization rates for inflammatory bowel disease in the United States. Clin Gastroenterol Hepatol 5: 597–601.
7. Bodini G. Savarino V. Fazio V. Assandri L. Dulbecco P. Gemignani L. et al. (2012) Relationship between drug serum concentration and clinical activity in patients with Crohn disease who achieved remission with adalimumab – a prospective study [abstract Sa2045]. Gastroenterology 142: S388.
8. Bosani M. Ardizzone S. Porro G.B. (2009) Biologic targeting in the treatment of inflammatory bowel diseases. Biologics 3: 77–97.
9. Brambell F. Hemmings W. Morris I. (1964) A theoretical model of gamma-globulin catabolism. Nature 203: 1352–1354.
10. Breese E. Michie C. Nicholls SW. Murch S. Williams C. Domizio P. et al. (1994) Tumor necrosis factor alpha-producing cells in the intestinal mucosa of children with inflammatory bowel disease. Gastroenterology 106: 1455–1466.
11. Bruining D. Sandborn W. (2011) Do not assume symptoms indicate failure of anti-tumor necrosis factor therapy in Crohn's disease. Clin Gastroenterol Hepatol 9: 395–399.
12. Candon S. Mosca A. Ruemmele F. Goulet O. Chatenoud L. Cezard J. (2006) Clinical and biological consequences of immunization to infliximab in pediatric Crohn's disease. Clin Immunol 118: 11–19.
13. Cassinotti A. Travis S. (2009) Incidence and clinical significance of immunogenicity to infliximab in Crohn's disease: a critical systematic review. Inflamm Bowel Dis 15: 1264–1275.
14. Colombel J. Feagan B. Sandborn W. van Assche G. Robinson A. (2011) Therapeutic drug monitoring of biologics for inflammatory bowel disease. Inflamm Bowel Dis 18: 349–359.
15. Colombel J. Sandborn W. Reinisch W. Mantzaris G. Kornbluth A. Rachmilewitz D. et al. (2010) Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 362: 1383–1395.
16. Colombel J. Sandborn W. Rutgeerts P. Enns R. Hanauer S. Panaccione R. et al. (2007) Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 132: 52–65.
17. Crohn's & Colitis Foundation of America (2007) Living with Crohn's disease. Available at: http://www.ccfa.org/about/press/ibdfacts (accessed 9 September 2011).
18. Dinesen L. Travis S. (2007) Targeting nanomedicines in the treatment of Crohn's disease: focus on certolizumab pegol (CDP870). Int J Nanomedicine 2: 39–47.
19. Drastich P. Kozeluhova J. Jaresova M. Spicak J. (2011) Infliximab serum trough levels and deep remission in patients with IBD [abstract Sa1371]. Gastroenterology 140: S292.
20. Farrell R. Alsahli M. Jeen Y. Falchuk K. Peppercorn M. Michetti P. (2003) Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial. Gastroenterology 124: 917–924.
21. Fasanmade A. Adedokun O. Blank M. Zhou H. Davis H. (2011) Pharmacokinetic properties of infliximab in children and adults with Crohn's disease: a retrospective analysis of data from 2 phase III clinical trials. Clin Ther 33: 946–964.
22. Feagan B. Singh S. Lockton S. Hauenstein S. Ohrmund L. Greenberg G. et al. (2012) Novel infliximab (IFX) & antibody-to-infliximab (ATI) assays are predictive of disease activity in patients with Crohn's disease (CD) [abstract 565]. Presented at 2012 Digestive Disease Week, 19–22 May 2012, San Diego, CA, USA.
23. Ferrante M. Karmiris K. Compernolle G. Ballet V. Vermeire S. Noman M. et al. (2011) Efficacy of adalimumab in patients with ulcerative colitis: restoration of serum levels after dose escalation results in a better long-term outcome [abstract OP312]. Presented at the Annual United European Gastroenterology Week, 22–26 October 2011, Stockholm, Sweden.
24. Han P. Cohen R. (2004) Managing immunogenic responses to infliximab: treatment implications for patients with Crohn's disease. Drugs 64: 1767–1777.
25. Hanauer S. Feagan B. Lichtenstein G. Mayer L. Schreiber S. Colombel J. et al. (2002) Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 359: 1541–1549.
26. Hanauer S. Sandborn W. Rutgeerts P. Fedorak R. Lukas M. MacIntosh D. et al. (2006) Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology 130: 323–333.
27. Hanauer S. Wagner C. Bala M. Mayer L. Travers S. Diamond R. et al. (2004) Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease. Clin Gastroenterol Hepatol 2: 542–553.
28. Hyams J. Crandall W. Kugathasan S. Griffiths A. Olson A. Johanns J. et al. (2007) Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children. Gastroenterology 132: 863–873.
29. Jess T. Riis L. Vind I. Winther K. Borg S. Binder V. et al. (2007) Changes in clinical characteristics, course, and prognosis of inflammatory bowel disease during the last 5 decades: a population-based study from Copenhagen, Denmark. Inflamm Bowel Dis 13: 481–489.
30. Karmiris K. Paintaud G. Noman M. Magdelaine-Beuzelin C. Ferrante M. Degenne D. et al. (2009) Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn's disease. Gastroenterology 137: 1628–1640.
31. Keizer R. Huitema A. Schellens J. Beijnen J. (2010) Clinical pharmacokinetics of therapeutic monoclonal antibodies. Clin Pharmacokinet 49: 493–507.
32. Langholz E. Munkholm P. Davidsen M. Binder V. (1994) Course of ulcerative colitis: analysis of changes in disease activity over years. Gastroenterology 107: 3–11.
33. Li J. Paulson S. Chiu Y. Robinson A. Lomax K. Pollack P. (2012) Evaluation of potential correlations between serum adalimumab concentration and remission in patients with Crohn's disease in classic I and II [abstract 741]. Gastroenterology 142: S101.
34. Lichtenstein G. Diamond R. Wagner C. Fasanmade A. Olson A. Marano C. et al. (2009) Clinical trial: benefits and risks of immunomodulators and maintenance infliximab for IBD-subgroup analyses across four randomized trials. Aliment Pharmacol Ther 30: 210–226.
35. Lichtenstein G. Thomsen O. Schreiber S. Lawrance I. Hanauer S. Bloomfield R. et al. (2010) Continuous therapy with certolizumab pegol maintains remission of patients with Crohn's disease for up to 18 months. Clin Gastroenterol Hepatol 8: 600–609.
36. Maser E. Villela R. Silverberg M. Greenberg G. (2006) Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease. Clin Gastroenterol Hepatol 4: 1248–1254.
37. Miele E. Markowitz J. Mamula P. Baldassano R. (2004) Human antichimeric antibody in children and young adults with inflammatory bowel disease receiving infliximab. J Pediatr Gastroenterol Nutr 38: 502–508.
38. Moss A. Fernandez-Becker N. Jo K. Cury D. Cheifetz A. (2008) The impact of infliximab infusion reactions on long-term outcomes in patients with Crohn's disease. Aliment Pharmacol Ther 28: 221–227.
39. Mould D. Green B. (2010) Pharmacokinetics and pharmacodynamics of monoclonal antibodies: concepts and lessons for drug development. BioDrugs 24: 23–39.
40. Munkholm P. Langholz E. Davidsen M. Binder V. (1995) Disease activity courses in a regional cohort of Crohn's disease patients. Scand J Gastroenterol 30: 699–706.
41. Murch S. Braegger C. Walker-Smith J. MacDonald T. (1993) Location of tumour necrosis factor alpha by immunohistochemistry in chronic inflammatory bowel disease. Gut 34: 1705–1709.
42. Nesbitt A. Fossati G. Bergin M. Stephens P. Stephens S. Foulkes R. et al. (2007) Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other anti-tumor necrosis factor alpha agents. Inflamm Bowel Dis 13: 1323–1332.
43. Raghavan M. Bjorkman P. (1996) Fc receptors and their interactions with immunoglobulins. Annu Rev Cell Dev Biol 12: 181–220.
44. Reinisch W. Feagan B. Rutgeerts P. Adedokun O. Cornillie F. Diamond R. et al. (2012) Infliximab concentration and clinical outcome in patients with ulcerative colitis [abstract 566]. Gastroenterology 142: S–114.
45. Rutgeerts P. Sandborn W. Feagan B. Reinisch W. Olson A. Johanns J. et al. (2005) Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 353: 2462–2476.
46. Sandborn W. (2003) Preventing antibodies to infliximab in patients with Crohn's disease: optimize not immunize. Gastroenterology 124: 1140–1145.
47. Sandborn W. Abreu M. D'Haens G. Colombel J. Vermeire S. Mitchev K. et al. (2010 a) Certolizumab pegol in patients with moderate to severe Crohn's disease and secondary failure to infliximab. Clin Gastroenterol Hepatol 8: 688–695.
48. Sandborn W. Feagan B. Hanauer S. Lochs H. Lofberg R. Modigliani R. et al. (2002) A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn's disease. Gastroenterology 122: 512–530.
49. Sandborn W. Feagan B. Stoinov S. Honiball P. Rutgeerts P. Mason D. et al. (2007 a) Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med 357: 228–238.
50. Sandborn W. Hanauer S. Pierre-Louis B. Lichtenstein G. (2012) Certolizumab pegol plasma concentration and clinical remission in Crohn's Disease [abstract Su2079]. Gastroenterology 142: S563.
51. Sandborn W. Hanauer S. Rutgeerts P. Fedorak R. Lukas M. MacIntosh D. et al. (2007 b) Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. Gut 56: 1232–1239.
52. Sandborn W. Rutgeerts P. Enns R. Hanauer S. Colombel J. Panaccione R. et al. (2007 c) Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med 146: 829–838.
53. Sandborn W. Schreiber S. Hanauer S. Colombel J. Bloomfield R. Lichtenstein G. (2010 b) Reinduction with certolizumab pegol in patients with relapsed Crohn's disease: results from the PRECiSE 4 Study. Clin Gastroenterol Hepatol 8: 696–702.
54. Schreiber S. Khaliq-Kareemi M. Lawrance I. Thomsen O. Hanauer S. McColm J. et al. (2007) Maintenance therapy with certolizumab pegol for Crohn's disease. N Engl J Med 357: 239–250.
55. Schreiber S. Rutgeerts P. Fedorak R. Khaliq-Kareemi M. Kamm M. Boivin M. et al. (2005) A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease. Gastroenterology 129: 807–818.
56. Seow C. Newman A. Irwin S. Steinhart A. Silverberg M. Greenberg G. (2010) Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis. Gut 59: 49–54.
57. Spector R. Park G. Johnson G. Vesell E. (1988) Therapeutic drug monitoring. Clin Pharmacol Ther 43: 345–353.
58. Tabrizi M. Tseng C. Roskos L. (2006) Elimination mechanisms of therapeutic monoclonal antibodies. Drug Discov Today 11: 81–88.
59. van Assche G. Magdelaine-Beuzelin C. D'Haens G. Baert F. Noman M. Vermeire S. et al. (2008) Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial. Gastroenterology 134: 1861–1868.
60. Vande Casteele N. Cuypers L. Singh S. Hauenstein S. Ohrmund L. Chuang E. et al. (2012 a) Transient versus sustained antibodies to infliximab: possibility to overcome low titer antibody responses by dose optimization [abstract P253]. Presented at the Annual Congress of the European Crohn's and Colitis Organisation, 16–18 February 2012, Barcelona, Spain.
61. Vande Casteele N. Cuypers L. Singh S. Hauenstein S. Ohrmund L. van Assche G. et al. (2012 b) Antibodies to infliximab can either be persistent or transient: a retrospective case-control study in IBD patients treated with infliximab maintenance therapy [abstract]. Presented at 2012 Digestive Disease Week, 19–22 May 2012, San Diego, CA, USA.
62. Vermeire S. Noman M. van Assche G. Baert F. D'Haens G. Rutgeerts P. (2007) Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease. Gut 56: 1226–1231.
63. West R. Zelinkova Z. Wolbink G. Kuipers E. Stokkers P. van der Woude C. (2008) Immunogenicity negatively influences the outcome of adalimumab treatment in Crohn's disease. Aliment Pharmacol Ther 28: 1122–1126.